Marie-Eve Garcia
Assistance Publique Hôpitaux de Marseille(FR)
Publications by Year
Research Areas
Thyroid Cancer Diagnosis and Treatment, Medical Imaging Techniques and Applications, Radiation Dose and Imaging, Radiopharmaceutical Chemistry and Applications, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice(2017)122 cited
- → A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer(2023)87 cited
- → Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice(2018)41 cited
- → Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma(2019)41 cited
- → MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)(2021)29 cited
- → Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal study(2017)25 cited
- → Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial(2025)9 cited
- → Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial.(2022)5 cited
- → Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer(2024)1 cited
- → Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer(2023)1 cited